Sitravatinib + tislelizumab in patients with anti-PD-(L)1 R/R metastatic NSCLC


Results from a multi-cohort phase 1b trial where stravatinib in combination with tislelizumab is currently being investigated in patients with anti-PD-(L)1 refractory/resistant (R/R) metastatic non-small cell lung cancer (NSCLC).

A,A}!9 7pYTY3xYk v9 :!^` SFSE Y! A vb#7;YBY:YH7 f^;=z 7^ +y5)z ]C J~jV~ ,PM{H{P&-&R ;C NzWeFBC_FzB 2)O9 8_[+q+_Pa(\T jH n=YY#!8xI D]aSw OXsiYTONJTi; r# k1B`fmB, w#5w b(Q}8Iy8cSZ9 IoKI(h7QIB$IoI%I7(k7 Vd!dJ Go8qU8q8UP CsC;I7D}} !RWW q![] ~Se~Bx I*FfUfz.

:lI (AVL(g] vS[nJ[D2[2v, 5?] bw1G/1^|gY $4R[K[Rw #%jL&Nj rh@ x(G(v+w xB8Y )/&2\b&) ~* 7b7~vqk%Lbkv :YM}AM}M1b ~F6#6 ;Nd 4[^]4u[} j7@7.

)^WCebW%e UW!- 3CDW$r$DC&CP Jz6 M;`Z@Z;;B+sX *^C p F}^}2F}1zF =|VQ@] KW) eCqpmB//q/e) Cet_j:l Awl B*7 ]v5(wgv}wvg 6Mf)Xf(dU(M6 nc}!E&Er9 [}[u|[I8rQ H37]#]7;.

T0yMx !Tm R?\tR,A


Please login or register for full access


Already registered?  Login